Physician profile
Amy E Shell
NPI 1750496253
$2,648.04
in general payments reported to CMS, 2019-2025
30 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.29 · 2023: $564 · 2024: $957 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,460 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,459.76 |
| Education | $175.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $327.16 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $307.46 | 2023-2025 | |
| Astellas Pharma US INC | $229.82 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.51 | 2023-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.26 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $144.89 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Exeltis, USA INC. | $130.63 | 2023-2025 | Slynd |
| Axsome Therapeutics, INC. | $123.73 | 2024-2025 | Auvelity |
| Mayne Pharma Commercial LLC | $103.77 | 2024-2025 | |
| Sage Therapeutics, LLC | $94.64 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $93.95 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $84.28 | 2024-2025 | Myfembree, Gemtesa |
| Shield Therapeutics INC | $75.23 | 2023-2024 | Accrufer |
| Exact Sciences Corporation | $74.08 | 2024-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $61.12 | 2025 | Axonics |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $53.64 | 2023-2025 | Nexplanon |
| Evofem Biosciences, INC. | $52.95 | 2023-2025 | Phexxi, Solosec, Phexx |
| Idorsia Pharmaceuticals US INC | $45.25 | 2023-2024 | Quviviq |
| Amgen INC. | $43.35 | 2022-2023 | Prolia, Evenity |
| Axonics, INC. | $40.30 | 2023-2024 | Axonics |
| Lundbeck LLC | $39.19 | 2024-2025 | Vyepti |
| Astrazeneca Pharmaceuticals LP | $29.81 | 2023-2024 | Breztri, Farxiga |
| Tonix Medicines, INC. | $23.75 | 2025 | Tonmya |
| Supernus Pharmaceuticals, INC. | $20.93 | 2025 | Qelbree |
| Lsi Solutions INC | $18.76 | 2025 | Fornisee |
| Scilex Pharmaceuticals INC. | $15.62 | 2023 | Ztlido |
| Merck Sharp & Dohme LLC | $14.72 | 2023 | Belsomra |
| Radius Health, INC. | $14.68 | 2024 | Tymlos |
| Ibsa Pharma INC. | $13.55 | 2023 | Tirosint, Licart |
| Channel Medsystems, INC. | $12.01 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Shell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.